Herein,the application of a N-doped graphitic-carbon-coated iron nitride composite dispersed in a N-doped carbon framework(Fe_(3)N@NG/NC)is investigated as a heterogeneous electro-Fenton(HE-EF)catalyst for the efficie...Herein,the application of a N-doped graphitic-carbon-coated iron nitride composite dispersed in a N-doped carbon framework(Fe_(3)N@NG/NC)is investigated as a heterogeneous electro-Fenton(HE-EF)catalyst for the efficient removal of organics.The simultaneous carbonization and ammonia etching of iron-based metal organic framework(Fe-MOF)materials yielded well-dispersed N-doped carbon-coated Fe_(3)N nanoparticles with a diameter of~70 nm.The Fe_(3)N and pyridinic N endowed the composite with high HE-EF activity for decomposing the electrogenerated H_(2)O_(2) to•OH.The Fe_(3)N@NG/NC exhibited outstanding HE-EF performance in removing various organic pollutants with low iron leaching.A removal rate of 97-100%could be obtained for rhodamine B(RhB),dimethyl phthalate,methylene blue,and orange Ⅱ in 120 min at a pH of 5.0.When the solution pH was set to 3.0,5.0,7.0,and 9.0,the removal rate of RhB reached 100%,96%,92%,and 81%,respectively,in 60 min at an optimum voltage of 0.0 V(vs.reversible hydrogen electrode(RHE)).Moreover,the concentration of leached iron was expected to be below 0.03 mg/L in a wide pH range of 3.0-9.0.In addition,the RhB removal efficiency remained as high as 90%after six cycles in the reusability experiments.This work highlights the MOF-derived Fe_(3)N composite as an efficient HE-EF catalyst and the corresponding catalytic mechanism,which facilitates its application in wastewater treatment.展开更多
It reveals that the MHC （major histocompatibility complex） gene product always involved in the control of immune response and disease resistance. Nowadays many studies have indicated the OLA （ovine lymphocyte anti...It reveals that the MHC （major histocompatibility complex） gene product always involved in the control of immune response and disease resistance. Nowadays many studies have indicated the OLA （ovine lymphocyte antigen） DRB1 gene is associated with some sheep diseases. Tibetan sheep is one of the three major shag sheep breeds in China, and also have the largest number of China＇s sheep breeds. But till now no report has been seen on studying DRB1 gene in Tibetan sheep of China. To understand the evolution and provide the basis for sheep disease resistance, polymorphism in the exon2 ofDRB1 gene in Tibetan sheep was analyzed. The PCR-SSCP, cloning and sequencing were used to analyse DRB1 gene variation in 600 Tibetan sheep of China. And the genetic relationship and evolutionary significance of the alleles had also been analyzed. Total of 31 alleles were identified, in which 15 alleles had not been reported before. And there were 70 SNPs （single nucleotide polymorphisms） sites in 31 sheep DRB1 gene haplotypes, the proportion was 29.5% to the whole exort2 sequence. All of this indicated that DRB1 exon2 is highly polymorphic in Tibetan sheep. The variation identified here might have an impact on both the function and level of expression of the OLA-DRB1.展开更多
Natural killer(NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex(MHC) matching, play pivotal roles in immune defence against tumors. However, tumo...Natural killer(NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex(MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability to escape NK cell-mediated immune surveillance. Thus, understanding mechanisms underlying regulation of NK cell phenotype and function within the tumor environment is instrumental for designing new approaches to improve the current cell-based immunotherapy. In this review, we elaborate the main biological features and molecular mechanisms of NK cells that pertain to regulation of NK cell-mediated anti-tumor activity. We further overview current clinical approaches regarding NK cell-based cancer therapy, including cytokine infusion, adoptive transfer of autologous or allogeneic NK cells, applications of chimeric antigen receptor(CAR)-expressing NK cells and adoptive transfer of memory-like NK cells. With these promising clinical outcomes and fuller understanding the basic questions raised in this review, we foresee that NK cell-based approaches may hold great potential for future cancer immunotherapy.展开更多
文摘Herein,the application of a N-doped graphitic-carbon-coated iron nitride composite dispersed in a N-doped carbon framework(Fe_(3)N@NG/NC)is investigated as a heterogeneous electro-Fenton(HE-EF)catalyst for the efficient removal of organics.The simultaneous carbonization and ammonia etching of iron-based metal organic framework(Fe-MOF)materials yielded well-dispersed N-doped carbon-coated Fe_(3)N nanoparticles with a diameter of~70 nm.The Fe_(3)N and pyridinic N endowed the composite with high HE-EF activity for decomposing the electrogenerated H_(2)O_(2) to•OH.The Fe_(3)N@NG/NC exhibited outstanding HE-EF performance in removing various organic pollutants with low iron leaching.A removal rate of 97-100%could be obtained for rhodamine B(RhB),dimethyl phthalate,methylene blue,and orange Ⅱ in 120 min at a pH of 5.0.When the solution pH was set to 3.0,5.0,7.0,and 9.0,the removal rate of RhB reached 100%,96%,92%,and 81%,respectively,in 60 min at an optimum voltage of 0.0 V(vs.reversible hydrogen electrode(RHE)).Moreover,the concentration of leached iron was expected to be below 0.03 mg/L in a wide pH range of 3.0-9.0.In addition,the RhB removal efficiency remained as high as 90%after six cycles in the reusability experiments.This work highlights the MOF-derived Fe_(3)N composite as an efficient HE-EF catalyst and the corresponding catalytic mechanism,which facilitates its application in wastewater treatment.
文摘It reveals that the MHC （major histocompatibility complex） gene product always involved in the control of immune response and disease resistance. Nowadays many studies have indicated the OLA （ovine lymphocyte antigen） DRB1 gene is associated with some sheep diseases. Tibetan sheep is one of the three major shag sheep breeds in China, and also have the largest number of China＇s sheep breeds. But till now no report has been seen on studying DRB1 gene in Tibetan sheep of China. To understand the evolution and provide the basis for sheep disease resistance, polymorphism in the exon2 ofDRB1 gene in Tibetan sheep was analyzed. The PCR-SSCP, cloning and sequencing were used to analyse DRB1 gene variation in 600 Tibetan sheep of China. And the genetic relationship and evolutionary significance of the alleles had also been analyzed. Total of 31 alleles were identified, in which 15 alleles had not been reported before. And there were 70 SNPs （single nucleotide polymorphisms） sites in 31 sheep DRB1 gene haplotypes, the proportion was 29.5% to the whole exort2 sequence. All of this indicated that DRB1 exon2 is highly polymorphic in Tibetan sheep. The variation identified here might have an impact on both the function and level of expression of the OLA-DRB1.
基金supported by grants from the Ministry of Science and Technology of China(2014CB910104)the National Natural Science Foundation of China(81171899+1 种基金81372230)the Claudia Adams Barr Program for Innovative Cancer Research
文摘Natural killer(NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex(MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability to escape NK cell-mediated immune surveillance. Thus, understanding mechanisms underlying regulation of NK cell phenotype and function within the tumor environment is instrumental for designing new approaches to improve the current cell-based immunotherapy. In this review, we elaborate the main biological features and molecular mechanisms of NK cells that pertain to regulation of NK cell-mediated anti-tumor activity. We further overview current clinical approaches regarding NK cell-based cancer therapy, including cytokine infusion, adoptive transfer of autologous or allogeneic NK cells, applications of chimeric antigen receptor(CAR)-expressing NK cells and adoptive transfer of memory-like NK cells. With these promising clinical outcomes and fuller understanding the basic questions raised in this review, we foresee that NK cell-based approaches may hold great potential for future cancer immunotherapy.
